{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:55:33Z","timestamp":1791078933168,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clml.2014.01.010","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T15:30:35Z","timestamp":1391527835000},"page":"297-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pralatrexate Alone or in Combination With Bexarotene: Long-Term Tolerability in Relapsed\/Refractory Mycosis Fungoides"],"prefix":"10.1016","volume":"14","author":[{"given":"Rakhshandra","family":"Talpur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Gangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.01.010_bib1","first-page":"277","article-title":"Cancer statistics","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2014.01.010_bib2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2014.01.010_bib3","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.01.010_bib4","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.3816\/CLM.2008.s.015","article-title":"Novel therapies for cutaneous T-cell lymphomas","volume":"8","author":"Horwitz","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2014.01.010_bib5","series-title":"T-Cell Malignancies: Recent Developments and Novel Therapeutic Approaches","first-page":"67","article-title":"Cutaneous T-cell lymphomas\u2014mycosis fungoides and S\u00e9zary syndrome","author":"Duvic","year":"2010"},{"key":"10.1016\/j.clml.2014.01.010_bib6","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.010_bib7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A\u00a0randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the\u00a0initial treatment of mycosis fungoides","volume":"32","author":"Kaye","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.01.010_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1067\/mjd.2003.449","article-title":"Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma","volume":"49","author":"Duvic","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2014.01.010_bib9","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2014.01.010_bib10","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for the treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.010_bib11","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.01.010_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.2001.tb03727.x","article-title":"Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up","volume":"941","author":"Wollina","year":"2001","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.clml.2014.01.010_bib13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2014.01.010_bib14","article-title":"Pralatrexate is an effective treatment for heavily pretreated patients with relapsed or refractory transformed mycosis fungoides (tMF)","volume":"116","author":"Foss","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.01.010_bib15","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.010_bib16","unstructured":"Duvic M, Zinzani PL, Geskin L, et\u00a0al. Pralatrexate plus bexarotene in patients with\u00a0relapsed or refractory cutaneous T-cell lymphoma (CTCL): study design and\u00a0preliminary results from an ongoing, open-label, phase 1 dose-finding study. Presented at the T-Cell Lymphoma Forum; January 26-28, 2012; San Francisco, CA."},{"key":"10.1016\/j.clml.2014.01.010_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200001040-00006","article-title":"Bexarotene","volume":"1","author":"Lowe","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clml.2014.01.010_bib18","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of\u00a0refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.010_bib19","first-page":"3493","article-title":"Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate","volume":"6","author":"Krug","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.01.010_bib20","first-page":"2072","article-title":"10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer","volume":"9","author":"Krug","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.01.010_bib21","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1158\/1078-0432.CCR-06-1754","article-title":"A\u00a0phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors","volume":"13","author":"Azzoli","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.01.010_bib22","first-page":"508","article-title":"Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignances","volume":"11","author":"Molina","year":"2008","journal-title":"IDrugs"},{"key":"10.1016\/j.clml.2014.01.010_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2217\/fon.12.168","article-title":"Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma","volume":"9","author":"Parker","year":"2013","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2014.01.010_bib24","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3109\/10428194.2013.779688","article-title":"Preemptive leucovorin administration minimizes\u00a0pralatrexate toxicity without sacrificing efficacy","volume":"54","author":"Koch","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.01.010_bib25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2014.01.010_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09546630802562427","article-title":"Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma","volume":"20","author":"Kannangara","year":"2009","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.clml.2014.01.010_bib27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:29Z","timestamp":1761870329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S2152265014000263"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.01.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pralatrexate Alone or in Combination With Bexarotene: Long-Term Tolerability in Relapsed\/Refractory Mycosis Fungoides","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}